We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Cassava Sciences (SAVA) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Cassava Sciences (SAVA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cassava Sciences is a member of the Medical sector. This group includes 977 individual stocks and currently holds a Zacks Sector Rank of #15. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. SAVA is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for SAVA's full-year earnings has moved 228.57% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, SAVA has moved about 659.97% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 5.40% on average. This means that Cassava Sciences is outperforming the sector as a whole this year.
To break things down more, SAVA belongs to the Medical - Drugs industry, a group that includes 190 individual companies and currently sits at #188 in the Zacks Industry Rank. On average, stocks in this group have gained 9.10% this year, meaning that SAVA is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track SAVA. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Cassava Sciences (SAVA) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Cassava Sciences (SAVA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cassava Sciences is a member of the Medical sector. This group includes 977 individual stocks and currently holds a Zacks Sector Rank of #15. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. SAVA is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for SAVA's full-year earnings has moved 228.57% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, SAVA has moved about 659.97% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 5.40% on average. This means that Cassava Sciences is outperforming the sector as a whole this year.
To break things down more, SAVA belongs to the Medical - Drugs industry, a group that includes 190 individual companies and currently sits at #188 in the Zacks Industry Rank. On average, stocks in this group have gained 9.10% this year, meaning that SAVA is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track SAVA. The stock will be looking to continue its solid performance.